Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis

Transplant Infectious Disease

Volumn 2, Issue 3, 2000, Pages 112-117

  Rubin, R H ^a   Kemmerly, S A ^b   Conti, D ^c   Doran, M ^a   Murray, B M ^d   Neylan, J F ^e   Pappas, C ^f   Pitts, D ^f   Avery, R ^g   Pavlakis, M ^h   Del Busto, R ⁱ   DeNofrio, D ^j   Blumberg, E A ^k   Schoenfeld, D A ^a   Donohue, T ^l   Fisher, S A ^m   Fishman, J A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b OCHSNER MEDICAL CENTER   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d ERIE COUNTY MEDICAL CENTER   (United States)

^e EMORY UNIVERSITY HOSPITAL   (United States)

^f METHODIST HOSPITAL   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h STANFORD UNIVERSITY MEDICAL CENTER   (United States)

ⁱ HENRY FORD HOSPITAL   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^l SAINT LOUIS UNIVERSITY   (United States)

^m RUSH UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Acyclovir; Cytomegalovirus; Ganciclovir; Organ transplantation

Indexed keywords

ACICLOVIR; GANCICLOVIR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MALE; MULTICENTER STUDY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIREMIA;

ACYCLOVIR; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; GANCICLOVIR; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; INJECTIONS, INTRAVENOUS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS;

EID: 0033812036     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2000.020303.x     Document Type: Article

References (15)

1. Infection in the organ transplant recipient
2. Infection in organ-transplant recipients
3. Cytomegalovirus infection and disease in solid organ transplant recipients
4. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation
5. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CVM-seronegative liver transplant recipients with CMV-seropositive donors
6. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
7. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
8. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3
9. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients
10. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir theray to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy
11. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double blind, placebo-controlled trial
12. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients
13. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients
14. Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients